5.02 Wording, acronym and label slips in Item 1 and Item 1A, most carried over from the prior-year Form 10-K
Company C · a US-listed specialty healthcare products company · Drafting slip
In brief
Thirteen small slips in Item 1 and Item 1A: a supplier name spelt two ways, a product labelled 'Lift' in the pipeline graphic but 'Form' in the text, a bullet split in the middle of a phrase, three misspelt acronyms, three garbled phrases, two risk-factor sub-captions not set in the bold italic used for the others, a currency risk factor that refers to 'these currencies' without naming any, and a cross-reference to 'contractual arrangements discussed above' that are not discussed. All but the graphic label, the first sub-caption and the currency sentence were also in the prior-year Form 10-K.
The evidence, as filed
6 further page extracts: screenshot withheld to protect the company’s identity. The rows below say what each shows.
What the filing shows, and what the rule requires
| What the filing shows | What the rule requires |
|---|---|
Printed page 6 '[supplier 1]' (page 2 and the exhibit index: '[supplier 1]'); graphic on page 6 'Lift' (text: 'Form'); page 9 the biologics license application (BLA) bullet broken after 'safety;'; page 13 'CRPA' (then 'CPRA'); page 16 first sub-caption in roman type; page 21 'demand or approval our products' and 'government files or penalties'; page 22 'the HIPPA' and 'BCPI Act'; page 25 'these currencies' with no currency named (the prior-year sentence naming the British pound and the euro was deleted); page 29 a second sub-caption in roman type; [n] 'may not be commercially or more available'; [n] 'restricted by the contractual arrangements discussed above', with no such arrangements discussed earlier. | '[supplier 1]'; 'Form' in the graphic; one bullet reading 'substantive evidence of safety, purity and potency'; 'CPRA'; bold italic sub-captions on pages 16 and 29; 'demand or approval for our products'; 'government fines or penalties'; 'HIPAA'; 'BPCI Act'; the currencies named again (as in the prior year) or the sentence recast; 'may not be available on commercially reasonable terms'; the cross-reference deleted or the restricting arrangements described. |
Why it matters
Cosmetic only; repeated slips in the risk factors suggest the section is rolled forward without a full proof-read.
Exposure
No regulatory consequence.
Our workings
Each slip is shown on its page below; the four later slips in Item 1A (printed pages 25 to 39) were found by a second reader and their pages are attached to this point. None changes a figure or a required disclosure; together they are proof-reading points for the next Form 10-K, where most have now been carried for two years. The currency sentence is the one slip made this year by an edit: deleting the line that named the currencies left the rest of the risk factor pointing at nothing.
Management’s best defense, and our reply
The Company could say these are immaterial typographical slips that no investor would misread, and that the 'Lift' label reflects the product's name in its partner's European range. Both points are accepted: the slips are listed only as drafting corrections, and the label should still match the name used in the text and on the US approval.
The fix
- Correct the thirteen slips listed in the should-be column and add a proof-reading pass of Items 1 and 1A against the defined-terms list and the cross-references before filing.
Evidence relied on
| # | What it shows | Type | Where |
|---|---|---|---|
| 1 | Supplier name spelt 'Pharmaceuticals' | Document | Form 10-K 2025, page 6 |
| 2 | The same supplier spelt 'Pharmaceutical' in the risk-factor summary (and in the exhibit index) | Document | Form 10-K 2025, page 2 |
| 3 | The text names the products Form and Smooth; the pipeline graphic below labels the first product 'Lift' in both the US and EU rows | Document | Form 10-K 2025, page 6 |
| 4 | The bullet ends after 'safety;' and the phrase continues as a new bullet 'purity and potency from results...' | Document | Form 10-K 2025, page 9 |
| 5 | Acronym defined as 'CRPA'; the next sentence uses 'CPRA' | Document | Form 10-K 2025, page 13 |
| 6 | First risk-factor sub-caption printed in roman type; the other sub-captions are bold italic, except a second one on p.29 | Document | Form 10-K 2025, page 16 |
| 7 | Garbled phrase (a word is missing) | Document | Form 10-K 2025, page 21 |
| 8 | 'files' for 'fines' | Document | Form 10-K 2025, page 21 |
| 9 | 'HIPPA' for HIPAA (defined correctly on p.11) | Document | Form 10-K 2025, page 22 |
| 10 | 'BCPI Act' for the 'BPCI Act' defined two lines above | Document | Form 10-K 2025, page 22 |
| 11 | The prior-year Form 10-K carried the same slip (as it did 'BCPI', 'CRPA', 'government files', 'approval our products', the split BLA bullet and 'Pharmaceuticals') | Document | Form 10-K 2024 (prior year), page 22 |
| 12 | currency risk factor: 'these currencies' with no currency named before it | Document | Form 10-K 2025, page 25 |
| 13 | prior-year Form 10-K named the currencies (British pound and euro); the sentence was deleted this year | Document | Form 10-K 2024 (prior year), page 25 |
| 14 | garbled phrase in the third-party infringement risk factor (should read 'available on commercially reasonable terms') | Document | Form 10-K 2025, page 30 |
| 15 | same phrase in the prior-year Form 10-K | Document | Form 10-K 2024 (prior year), page 30 |
| 16 | future-sales risk factor cross-refers to contractual arrangements that are not discussed anywhere above | Document | Form 10-K 2025, page 39 |
| 17 | same dangling cross-reference in the prior-year Form 10-K | Document | Form 10-K 2024 (prior year), page 38 |
| 18 | a second risk sub-caption printed in roman body type, unlike the bold italic used for the others | Document | Form 10-K 2025, page 29 |
| 19 | same unformatted sub-caption in the prior-year Form 10-K | Document | Form 10-K 2024 (prior year), page 28 |
Prepared by Pramanex from the company’s public SEC filings, without the company’s involvement, to show how a 10-K Pre-filing Check reads. The company is not named, and nothing on this page is a statement about any identifiable company. Observations are not an audit, review or other attestation or assurance engagement, and not legal advice. An SEC-style question is a question, not a conclusion.
Want this on your own 10-K, before you file?
Start with three free findings on your latest 10-K, or book a fixed-price 10-K Pre-filing Check.
Your next 10-K will be in draft before the audit is done.
Have it read before you file.
Start with three free findings on your latest 10-K, or book a fixed-price 10-K check. Drafts only under NDA, inside your insider trading policy.